Free Trial
NASDAQ:OCS

Oculis (OCS) Stock Price, News & Analysis

Oculis logo
$7.61 -0.03 (-0.43%)
Closing price 03:59 PM Eastern
Extended Trading
$7.63 +0.02 (+0.30%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Oculis Stock (NASDAQ:OCS)

Advanced

Key Stats

Today's Range
$7.54
▼
$8.21
50-Day Range
$6.83
▼
$12.17
52-Week Range
$6.78
▼
$34.47
Volume
165,568 shs
Average Volume
415,347 shs
Market Capitalization
$441.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.57
Consensus Rating
Moderate Buy

Company Overview

Oculis is a clinical-stage biopharmaceutical company developing treatments for eye diseases. Founded in 2017, the company is headquartered in Switzerland and conducts research and development across multiple locations.

Its investigational pipeline includes therapies for conditions such as diabetic macular edema, dry eye disease and optic neuritis. The programs use approaches including topical eye-drop delivery and neuroprotection, with candidates at different stages of clinical development.

Oculis focuses on developing treatments for patients worldwide. Its therapies remain investigational, and the company’s work is centered on advancing candidates through clinical testing and regulatory review.

AI Generated. May Contain Errors.

Oculis Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
53rd Percentile Overall Score

OCS MarketRank™: 
2.667682926825 of 5 stars

Oculis scored higher than 53% of companies evaluated by MarketBeat, and ranked 540th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Oculis has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 7 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Oculis has a consensus price target of $38.57, representing about 406.2% upside from its current price of $7.62.

  • Amount of Analyst Coverage

    Oculis has only been the subject of 3 research reports in the past 90 days.

  • Read more about Oculis' stock forecast and price target.
  • Earnings Growth

    Earnings for Oculis are expected to decrease in the coming year, from ($1.83) to ($1.95) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Oculis is -4.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Oculis is -4.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Oculis has a P/B Ratio of 1.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.73% of the float of Oculis has been sold short.
  • Short Interest Ratio / Days to Cover

    Oculis has a short interest ratio ("days to cover") of 5.64.
  • Change versus previous month

    Short interest in Oculis has recently decreased by 11.34%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Oculis does not currently pay a dividend.

  • Dividend Growth

    Oculis does not have a long track record of dividend growth.

  • News Sentiment

    Oculis has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Oculis this week, compared to 5 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Oculis insiders have not sold or bought any company stock.

  • Percentage Held by Institutions

    22.30% of the stock of Oculis is held by institutions.

  • Read more about Oculis' insider trading history.
Receive OCS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oculis and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

OCS Stock News Headlines

Your Social Security check is scheduled for a 22% cut
The U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold.tc pixel
Oculis Gains FDA IND Clearance for Privosegtor in Acute MS Relapses
See More Headlines

OCS Stock Analysis - Frequently Asked Questions

Oculis' stock was trading at $19.97 at the start of the year. Since then, OCS stock has decreased by 61.8% and is now trading at $7.62.

Oculis Holding AG (NASDAQ:OCS) released its quarterly earnings data on Tuesday, November, 3rd. The company reported ($0.37) EPS for the quarter, beating analysts' consensus estimates of ($0.47) by $0.10. The business earned $8.38 thousand during the quarter, compared to analyst estimates of $260 thousand. Oculis had a negative net margin of 8,613.92% and a negative trailing twelve-month return on equity of 39.24%.

Oculis' top institutional investors include Marshall Wace LLP (0.45%), Checkpoint Capital L.P. (0.17%), Alps Advisors Inc. (0.14%) and Aberdeen Group plc (0.12%).

Shares of OCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oculis investors own include ARM (ARM), Broadcom (AVGO), CervoMed (CRVO), KLA (KLAC), Microchip Technology (MCHP), Marvell Technology (MRVL) and Micron Technology (MU).

Company Calendar

Last Earnings
11/03/2026
Today
11/16/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:OCS
CIK
1953530
Fax
N/A
Employees
60
Year Founded
2017

Price Target and Rating

High Price Target
$55.00
Low Price Target
$20.00
Potential Upside/Downside
+407.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.71)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$119.44 million
Net Margins
-8,613.92%
Pretax Margin
-8,844.59%
Return on Equity
-39.24%
Return on Assets
-33.45%

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
10.41
Quick Ratio
10.41

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.08 per share
Price / Book
1.86

Miscellaneous

Outstanding Shares
57,984,000
Free Float
N/A
Market Cap
$441.14 million
Optionable
Optionable
Beta
0.67

Social Links

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

This page (NASDAQ:OCS) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners